Pith. sign in

REVIEW 4 major objections 4 minor 1 cited by

Devising PoPStat: A Metric Bridging Population Pyramids with Global Disease Mortality

T0 review · 4 major / 4 minor · reviewed 2026-08-10 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read The paper claims that a single scalar measure of population-pyramid shape, PoPStat, explains disease-specific mortality better than median age, GDP per capita, or the Human Development Index for most of the 371 diseases studied.

desk verdict PoPStat's outperformance claim is an artifact of brute-force reference selection; the underlying KL-divergence idea is reasonable but the evidence is fitted. read the letter →

arxiv 2501.11514 v2 pith:KFJYR3ME submitted 2025-01-20 stat.AP

Tharaka Fonseka , Buddhi Wijenayake , Athulya Ratnayake , Inosha Alwis , Supun Manathunga , Roshan Godaliyadda , Samath Dharmarathne , Vijitha Herath
show 2 more authors
Parakrama Ekanayake Isuru Pamuditha
This is my paper · ORCID
classification stat.AP
keywords populationpyramidsPoPStatPDivergencedemographictransitionepidemiologicaldisease-specificmortalityKullback-Leiblerdivergencereferencecountrytuning
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This paper introduces a single number, PoPStat, meant to capture how tightly a country's population pyramid shape is bound to death rates from a given disease. The authors compress each country's age-sex distribution into a divergence distance from a reference pyramid, then correlate those distances with logged mortality across countries. They report that this score beats standard indicators such as median age, GDP per capita, and the Human Development Index for most of the 371 diseases examined. If correct, the metric would give health planners a demographic early-warning signal and would provide quantitative support for the idea that disease burdens shift in a predictable way as populations age.

What carries the argument

The central object is PoPDivergence, defined as the Kullback-Leibler divergence between a country's age-sex distribution $P$ and a reference distribution $Q$: $D_{\mathrm{KL}}(P \| Q) = \sum_i P(i) \log(P(i)/Q(i))$. PoPStat is then the Pearson correlation between these divergence values and the natural log of cause-specific death rates. The reference $Q$ is not fixed a priori: a brute-force search over all 180 candidate countries selects the reference that maximizes that correlation for each disease. This reference tuning lets a single scalar order countries along the demographic transition, but it also means the reported correlation is the maximum of 180 candidate correlations rather than an independently specified one.

What would settle it

Compute PoPStat with the reference country fixed before seeing mortality data, or use a holdout set of countries excluded from the reference search, and check whether the correlation remains as high as reported; alternatively, permute mortality labels across countries to build a null distribution for the maximum-of-180 correlation.

Watch

Extended reading notes

Core claim

On the paper's own terms, the central discovery is that the full age-sex shape of a population, rather than its median age or wealth, carries much of the demographic signal in disease-specific mortality. For non-communicable diseases the association is strong and negative, with a PoPStat of $-0.84$ using Japan as the optimized reference: mortality concentrates in constrictive, aging pyramids. Communicable, maternal, neonatal, and nutritional diseases show a moderate positive association ($0.50$, Singapore reference), with the burden in expansive, young pyramids, while injuries are only weakly tied to pyramid shape ($0.29$). The metric also identifies causes that are demographically 'free,' such as diabetes, respiratory infections, cirrhosis, self-harm, and interpersonal violence, all of which show weak PoPStat values. The authors interpret the overall pattern as empirical confirmation of the epidemiological transition model, with the optimized reference country marking the demographic archetype that best orders all countries along the transition.

Load-bearing premise

The reference population is chosen by brute-force optimization to maximize the correlation with mortality, so PoPStat is a maximum of many candidate correlations and its reported strength is not an independent estimate.

Editorial extensions

If this is right

  • Non-communicable disease mortality is largely a demographic phenomenon: aging, constrictive pyramids carry the burden, so countries mid-transition can expect rising NCD loads as their pyramids constrict.
  • Communicable, maternal, and neonatal mortality tracks expansive pyramids, so population structure alone flags where these burdens concentrate.
  • Because PoPDivergence orders countries along the demographic transition in a single cross-section, it offers a shortcut for studying demographic and epidemiological change without decades of longitudinal data.
  • The same divergence score can be correlated with any social, behavioral, or economic outcome, extending the metric beyond mortality.
  • Diseases with weak PoPStat values, such as diabetes, respiratory infections, and injuries, are exactly where demographic structure explains little and policy must look to other determinants.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • Because the reference country is chosen by maximizing the correlation on the same data, the reported PoPStat values are probably optimistic; a permutation test or cross-validated reference choice would give unbiased estimates of how much population shape actually explains.
  • A direct test would fix the reference country from one disease (for instance, Japan for NCDs) and apply it to another cause or a later year, checking whether the pre-specified correlation holds out of sample.
  • The same divergence machinery could be applied to other population-level exposures, such as income distributions, education structures, or urban-rural splits, to see whether a single shape scalar is generally more informative than summary statistics.
  • For countries with missing death data, PoPStat suggests an imputation strategy based on pyramid shape alone, but any prediction interval must account for the selection bias in the reference choice.
Share X Bluesky LinkedIn Reddit HN

Signed reviews

No signed human review yet.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

4 major / 4 minor

Summary. The manuscript introduces two metrics, PoPDivergence (a KL-divergence between a country's population pyramid and a reference pyramid) and PoPStat (the Pearson correlation between PoPDivergence and the natural log of disease-specific mortality). The reference pyramid is selected per disease by brute-force optimization (Eq. 2) to maximize the correlation with mortality. Using GBD 2021 mortality data and UN WPP 2024 population data, the authors report PoPStat values for 371 diseases across countries and claim that PoPStat outperforms median age, GDP per capita, and HDI in explaining mortality for most diseases. They also interpret the signs of PoPStat in terms of expansive versus constrictive pyramids and link their findings to the epidemiological transition model.

Significance. If the central claim were valid, a scalar population-structure metric that outperforms standard demographic and development indicators would be a useful tool for mortality forecasting and health-policy targeting. The paper draws on comprehensive public datasets and provides code and scripts on GitHub, which is a strength for reproducibility. However, the statistical validity of the headline claim is undermined by the reference-selection procedure, which fits the metric to the outcome. The paper would be valuable if the authors could demonstrate, through out-of-sample validation or selection-corrected inference, that PoPStat retains predictive superiority over fixed indicators.

major comments (4)
  1. [§2.3, Eq. (2)] The reference population is chosen by maximizing the correlation between PoPDivergence and log mortality for each disease. Thus the reported PoPStat is the maximum over roughly 180 candidate correlations. Under a null hypothesis of no true association, the maximum of many noisy correlations is expected to be far from zero, so the reported magnitudes (e.g., –0.846 for NCDs in Table 1) are inflated by selection. The p-values and confidence intervals in Tables 1–2 are nominal and do not account for the arg max over references; they are therefore not valid for the optimized PoPStat. The authors must provide a selection-corrected null distribution (e.g., a permutation test that repeats the reference optimization) or out-of-sample correlation estimates before any claim about the strength of association can be accepted.
  2. [§2.5 and Abstract] The comparison with median age, GDP per capita, and HDI is not balanced because PoPStat is allowed to select the best reference population per disease, whereas these comparator indicators are fixed with no analogous optimization. The observed 'outperformance' is at least partly a byproduct of overfitting the reference choice. To support the claim that PoPStat outperforms traditional indicators, the authors should evaluate all indicators out-of-sample: split the sample, choose the reference on a training set, and compute correlations on a validation set, while also permitting the comparators a comparable level of flexibility (e.g., transformations). Without such a procedure, the headline claim in the abstract is not established.
  3. [§2.3, Eq. (2) and Table 1] There is an apparent inconsistency between the stated objective, arg max_{ω} Cor[ln S, PoPDivergence(ω)], and the reported negative PoPStat values (e.g., –0.846 for NCDs with Japan as reference). If the objective is to maximize the signed correlation, the selected reference should yield the largest positive correlation; if instead the objective is to maximize the absolute correlation, then the sign of PoPStat is an artifact of the chosen reference and cannot be directly interpreted as evidence that mortality is concentrated in constrictive or expansive pyramids. The paper should clarify which objective is used and, accordingly, temper the interpretive statements in §4.3 about 'constrictive' versus 'expansive' burden.
  4. [§3 and Table 1] The reported 'explained variance' values, such as 81.4% for NCDs, are presented as if they were the R-squared of a pre-specified model. Because the reference is selected to maximize the correlation, these values are in-sample fitting results rather than unbiased estimates of explanatory power. The authors should either use cross-validated R-squared or explicitly label these as in-sample descriptive quantities without inferential claims about the proportion of mortality variation explained by population structure.
minor comments (4)
  1. [Abstract and §2.1] The abstract states that the metrics were applied across 204 countries, while the Methods section reports mortality data for 180 countries. This inconsistency should be reconciled.
  2. [Eq. (1)] PoPDivergence is defined as a KL divergence, which is asymmetric in its arguments. The paper does not discuss how the choice of reference affects the distribution of PoPDivergence values across countries, although this is relevant to the interpretability of the metric's direction.
  3. [Table 1] The p-value for respiratory infections and tuberculosis is reported as 0.055 in the text, which is not significant at conventional levels. The paper should state explicitly that this association is not statistically significant (after multiple-comparison considerations) or refrain from discussing it as a 'weak association' without this caveat.
  4. [Abstract] The phrase 'PoPStat of (0.291, Singapore, < 0.001)' omits the 'p' before the p-value; this format should be made consistent throughout.

Circularity Check

1 steps flagged · score 7.0 of 10

PoPStat's reference country is chosen by brute-force maximization of the outcome correlation (Eq. 2), making the reported association a selected maximum over 180 candidates and the benchmark against fixed indicators favorable by construction.

  1. fitted input called prediction [Section 2.3 (Reference Country Tuning), Eq. 2; Section 2.4 (Constructing the PoPStat), Eq. 3]
    "Since, the PoPDivergence values depend on a pre selected reference country, to maximize correlation with cause specific mortality rates (expressed as the natural log of deaths per million), we optimize the reference selection using the objective function 2, arg max_{ω∈Ω} Cor [ln S, PoP Divergence(ω)] (2) where Ω is the set of countries, and S is the mortality rates. Given the absence of a closed form solution, brute force search identifies the reference pyramid with the strongest correlation to mortality."

    PoPStat is defined in Eq. 3 as the Pearson correlation between PoPDivergence and ln(mortality), while Eq. 2 selects the reference country ω to maximize exactly that correlation. Therefore, for each disease, the reported PoPStat is by construction max_{ω∈Ω} Cor[ln S, PoPDivergence(ω)] over 180 candidate reference countries. The value reported as an association (e.g., -0.846 for NCDs) is thus a selected maximum, not an independent estimate from a fixed metric. The later comparison with median age, GDP, and HDI (Section 2.5) is unfair because those indicators receive no analogous optimization; under the null, the maximum of 180 correlations is expected to be positive, and the nominal p-values are not corrected for this selection.

full rationale

The paper's own equations exhibit the specific reduction: Eq. 2 defines the reference by arg max of the outcome correlation, and Eq. 3 defines PoPStat as that correlation. Hence the central headline result—that PoPStat outperforms median age, GDP, and HDI—rests on comparing a statistic that has been optimized against the outcome to fixed indicators that have not. No self-citation chain or imported uniqueness theorem is involved; the circularity is the fitting of the reference to the dependent variable and then presenting the fitted maximum as an unadjusted association. The paper contains independent empirical content (e.g., which diseases have strong versus weak associations, and the signs of the associations), which is why the score is not higher, but the specific outperformance claim is inflated by construction and would require selection-aware corrections, pre-specified references, or out-of-sample validation to be interpretable as an independent finding.

Assumptions & free parameters 1 free parameters · 3 assumptions · 0 invented entities

No new physical or metaphysical entities; the paper invents metrics, which are not listed here.

free parameters (1)
  • Reference country per disease = e.g., Japan for NCD, Singapore for CMNN
    Selected by brute-force maximizing the correlation between PoPDivergence and log mortality (Section 2.3, Eq. 2). This is a free parameter fitted to the outcome.
assumptions (3)
  • domain assumption KL divergence is an appropriate distance measure for comparing population pyramids
    Section 2.2 assumes that the KL divergence between age-sex distributions is a meaningful scalar summary.
  • domain assumption Mortality rates are accurately represented by GBD 2021 and population data by UN WPP 2024
    Data sources in Section 2.1; no validation of measurement error.
  • domain assumption Pearson correlation on log mortality linearly captures the association
    Section 2.4; no check for nonlinearity or outliers.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Devising PoPStat: A Metric Bridging Population Pyramids with Global Disease Mortality." pith.science (2026). https://pith.science/paper/KFJYR3ME

@misc{pith2026250111514,
  author       = {Pith},
  title        = {Pith review of: Devising PoPStat: A Metric Bridging Population Pyramids with Global Disease Mortality},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/KFJYR3ME}},
  note         = {Machine review of arXiv:2501.11514}
}
read the original abstract

Understanding the relationship between population dynamics and disease-specific mortality is central to evidence-based health policy. This study introduces two novel metrics, PoPDivergence and PoPStat, one to quantify the difference between population pyramids and the other to assess the strength and nature of their association with the mortality of a given disease. PoPDivergence, based on Kullback-Leibler divergence, measures deviations between a countrys population pyramid and a reference pyramid. PoPStat is the correlation between these deviations and the log form of disease-specific mortality rates. The reference population is selected by a brute-force optimization that maximizes this correlation. Utilizing mortality data from the Global Burden of Disease 2021 and population statistics from the United Nations, we applied these metrics to 371 diseases across 204 countries. Results reveal that PoPStat outperforms traditional indicators such as median age, GDP per capita, and Human Development Index in explaining the mortality of most diseases. Noncommunicable diseases (NCDs) like neurological disorders and cancers, communicable diseases (CDs) like neglected tropical diseases, and maternal and neonatal diseases were tightly bound to the underlying demographic attributes whereas NCDs like diabetes, CDs like respiratory infections and injuries including self-harm and interpersonal violence were weakly associated with population pyramid shapes. Notably, except for diabetes, the NCD mortality burden was shared by constrictive population pyramids, while mortality of communicable diseases, maternal and neonatal causes and injuries were largely borne by expansive pyramids. Therefore, PoPStat provides insights into demographic determinants of health and empirical support for models on epidemiological transition. Code and scripts: https://github.com/Buddhi19/DevisingPoPStat.git

Figures

Figures reproduced from arXiv: 2501.11514 by the authors.

Figure 1
Figure 1. Differences in median age, life expectancy, and population density, together with the corresponding variations in population structure. visualization of population pyramids allows them to capture the entire age-sex spectrum of a country overcoming the limitations of traditional demographic variables. Nevertheless, no methodological approach has yet been proposed in literature to condense these information rich struc… view at source ↗
Figure 2
Figure 2. Prominent population pyramid structures The evolution of the population pyramid from an expansive to a constrictive shape is best explained by the landmark Demographic Transition Model (DTM) introduced by Warren Thompson. Though this transformation is directly driven by birth, death, and migration rates as proposed by the DTM, it is also closely associated with policy changes, economic shifts, natural disasters and,… view at source ↗
Figure 3
Figure 3. Comparison of PoPDivergence values across countries. Top row: Central African Republic as reference, [PITH_FULL_IMAGE:figures/full_fig_p004_3.png] view at source ↗
Figures from the paper (2 more)
Figure 4
Figure 4. Figure 4: PoPDiveregence vs Disease Mortality for Selected High Impact Disease Categories [PITH_FULL_IMAGE:figures/full_fig_p006_4.png]
Figure 5
Figure 5. Figure 5: PoPStat of Ischemic heart diseases against correlations with other indicators [PITH_FULL_IMAGE:figures/full_fig_p007_5.png]

Discussion (0). Continue with ORCID to comment.

Forward citations

Cited by 1 Pith paper

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score. Full citation record

  1. PoPStat-COVID19: Leveraging Population Pyramids to Quantify Demographic Vulnerability to COVID-19

    stat.AP 2025-09 reject novelty 4.0 of 10

    The paper reports that KL divergence of national population pyramids from Malta's pyramid correlates strongly with COVID-19 cases (r=-0.86) and deaths (r=-0.82), but the reference was chosen to maximize that correlation.

Reference graph

Works this paper leans on

44 extracted references · 41 canonical work pages · cited by 1 Pith paper

  1. [1]

    Deaths per year

    in Data OW. Deaths per year;. Available from: https://ourworldindata.org/grapher/ number-of-deaths-per-year

    work page

  2. [2]

    Wang H. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017 Sep;390(10100):1084-150. Available from: https://doi.org/10.1016/s0140-6736(17)31833-0

    work page doi:10.1016/s0140-6736(17)31833-0 1970

  3. [3]

    Global cancer transitions according to the Human Development Index (2008–2030): a population- based study

    Bray F. Global cancer transitions according to the Human Development Index (2008–2030): a population- based study. The Lancet Oncology. 2012 Aug;13(8):790-801. Available from: https://doi.org/10.1016/ s1470-2045(12)70211-5

    work page 2008

  4. [4]

    Fullman N. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. The Lancet. 2018 Jun;391(10136):2236-71. Available from: https://doi.org/10.1016/s0140-6736(18) 30994-2

    work page doi:10.1016/s0140-6736(18 2016

  5. [5]

    Work as a social determinant of health in high-income countries: past, present, and future

    Frank J. Work as a social determinant of health in high-income countries: past, present, and future. The Lancet. 2023 Oct;402(10410):1357-67. Available from: https://doi.org/10.1016/s0140-6736(23)00871-1

    work page doi:10.1016/s0140-6736(23)00871-1 2023

  6. [6]

    Decreasing median age of COVID-19 cases in the United States—Changing epidemiology or changing surveillance? PLOS ONE

    Greene DN. Decreasing median age of COVID-19 cases in the United States—Changing epidemiology or changing surveillance? PLOS ONE. 2020 Oct;15(10):e0240783. Available from: https://doi.org/10.1371/ journal.pone.0240783. 13

    work page 2020

  7. [7]

    Association between ageing population, median age, life expectancy and mortality in coronavirus disease (COVID-19)

    Wang XQ. Association between ageing population, median age, life expectancy and mortality in coronavirus disease (COVID-19). Aging. 2020 Dec;12(24):24570-8. Available from: https://doi.org/10.18632/aging. 104193

    work page doi:10.18632/aging 2020

  8. [8]

    HAEMOPHILUS INFLUENZAE DISEASE IN ALASKAN ESKIMOS: CHARACTERISTICS OF A POPULATION WITH AN UNUSUAL INCIDENCE OF INV ASIVE DISEASE

    Ward J. HAEMOPHILUS INFLUENZAE DISEASE IN ALASKAN ESKIMOS: CHARACTERISTICS OF A POPULATION WITH AN UNUSUAL INCIDENCE OF INV ASIVE DISEASE. The Lancet. 1981 Jun;317(8233):1281-5. Available from: https://doi.org/10.1016/s0140-6736(81)92458-2

    work page doi:10.1016/s0140-6736(81)92458-2 1981

Show all 44 references
  1. [9]

    Requirements for global elimination of hepatitis B: a modelling study

    Nayagam S. Requirements for global elimination of hepatitis B: a modelling study. The Lancet Infectious Diseases. 2016 Dec;16(12):1399-408. Available from: https://doi.org/10.1016/s1473-3099(16)30204-3

    2016 doi

  2. [10]

    Effect of population density on epidemics

    Li R. Effect of population density on epidemics. Physica A: Statistical Mechanics and its Applications. 2018 Nov;510:713-24. Available from: https://doi.org/10.1016/j.physa.2018.07.025

    2018 doi

  3. [11]

    Is Population Density Associated with Non-Communicable Disease in Western Developed Countries? A Systematic Review

    Carnegie ER. Is Population Density Associated with Non-Communicable Disease in Western Developed Countries? A Systematic Review. International Journal of Environmental Research and Public Health. 2022 Feb;19(5):2638. Available from: https://doi.org/10.3390/ijerph19052638

    2022 doi

  4. [12]

    Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010

    Ferrari AJ. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. PLoS Medicine. 2013 Nov;10(11):e1001547. Available from: https://doi.org/10. 1371/journal.pmed.1001547

    2010

  5. [13]

    Types and Significance of Population Pyramids

    Wwjmrd. Types and Significance of Population Pyramids. International Journal Peer Reviewed Journal Refereed Journal Indexed Journal UGC Approved Journal Impact Factor. 2018;4:59-69. Available from: www.wwjmrd.com

    2018

  6. [14]

    Ending an Era of Population Control in China: Was the One-Child Policy Ever Needed? The American Journal of Economics and Sociology

    Wang Z. Ending an Era of Population Control in China: Was the One-Child Policy Ever Needed? The American Journal of Economics and Sociology. 2016 Sep;75(4):929-79. Available from: https://doi.org/10.1111/ ajes.12160

    2016

  7. [15]

    The Epidemiologic Transition: A Theory of the Epidemiology of Population Change

    OMRAN AR. The Epidemiologic Transition: A Theory of the Epidemiology of Population Change. The Milbank Quarterly. 2005 Dec;83(4):731-57. Available from: https://doi.org/10.1111/j.1468-0009.2005.00398. x

    2005

  8. [16]

    A WIDE-BASE POPULATION PYRAMID AND OTHER FACTORS EXPLAIN LOW MORTALITY IN PAKISTAN DURING COVID-19 PANDEMIC

    Khan F. A WIDE-BASE POPULATION PYRAMID AND OTHER FACTORS EXPLAIN LOW MORTALITY IN PAKISTAN DURING COVID-19 PANDEMIC. Journal of Ayub Medical College Abbottabad. 2022 Jun;34(3):581-

    2022

  9. [17]

    Available from: https://doi.org/10.55519/jamc-03-9444

    doi

  10. [18]

    The Changing Relation between Mortality and Level of Economic Development

    Preston SH. The Changing Relation between Mortality and Level of Economic Development. Population Studies. 1975 Jul;29(2):231. Available from: https://doi.org/10.2307/2173509

    1975 doi

  11. [19]

    The Global Burden of Unintentional Injuries and an Agenda for Progress

    Chandran A. The Global Burden of Unintentional Injuries and an Agenda for Progress. Epidemiologic Reviews. 2010 Apr;32(1):110-20. Available from: https://doi.org/10.1093/epirev/mxq009

    2010 doi

  12. [20]

    The development and experience of epidemiological transition theory over four decades: a systematic review

    Santosa A. The development and experience of epidemiological transition theory over four decades: a systematic review. Global Health Action. 2014 Dec;7(1). Available from: https://doi.org/10.3402/gha.v7.23574

    2014 doi

  13. [21]

    Global socioeconomic inequality in the burden of communicable and non-communicable diseases and injuries: an analysis on global burden of disease study 2019

    Emadi M. Global socioeconomic inequality in the burden of communicable and non-communicable diseases and injuries: an analysis on global burden of disease study 2019. BMC Public Health. 2021 Dec;21(1). Available from: https://doi.org/10.1186/s12889-021-11793-7

    2019 doi

  14. [22]

    Burden of non-communicable diseases due to population ageing in China: challenges to healthcare delivery and long term care services

    Lv Y . Burden of non-communicable diseases due to population ageing in China: challenges to healthcare delivery and long term care services. BMJ. 2024 Oct:e076529. Available from: https://doi.org/10.1136/ bmj-2023-076529

    2024

  15. [23]

    Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries

    Katzmarzyk PT. Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries. British Journal of Sports Medicine. 2022 Jan;56(2):101-6. Available from: https: //doi.org/10.1136/bjsports-2020-103640

    2022 doi

  16. [24]

    Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

    Griswold MG. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2018 Sep;392(10152):1015-35. Available from: https://doi.org/10.1016/s0140-6736(18)31310-2

    1990 doi

  17. [25]

    Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015

    Forouzanfar MH. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017 Jan;317(2):165. Available from: https://doi.org/10.1001/jama.2016.19043

    1990

  18. [26]

    Reitsma MB. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. The Lancet. 2021 Jun;397(10292):2337-60...

    1990

  19. [27]

    The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

    Degenhardt L. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Psychiatry. 2018 Dec;5(12):987-1012. Available from: https://doi.org/10.10...

    1990 doi

  20. [28]

    Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019

    Chong B. Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019. eClinicalMedicine. 2023 Mar;57:101850. Available from: https: //doi.org/10.1016/j.eclinm.2023.101850

    2019

  21. [29]

    Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015

    Cohen AJ. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. The Lancet. 2017 May;389(10082):1907-18. Available from: https://doi.org/10.1016/s0140-6736(17)30505-6

    2015 doi

  22. [30]

    Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016

    undefined undefined. Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. Occupational and Environmental Medicine. 2020 Mar;77(3):151-9. Available from: https...

    2016 doi

  23. [31]

    Troeger C. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Infectious Diseases. 2018 Nov;18(11):1211-28. Available from: https://d...

    2016 doi

  24. [32]

    a systematic analysis for the Global Burden of Disease Study 2021

    Ferrari AJ. a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024 May;403(10440):2133-61. Available from: https://doi.org/10.1016/s0140-6736(24)00757-8

    2021 doi

  25. [33]

    Prevalence and attributable health burdens of vector-borne parasitic infectious diseases of poverty, 1990–2021: findings from the Global Burden of Disease Study 2021

    Zhu YS. Prevalence and attributable health burdens of vector-borne parasitic infectious diseases of poverty, 1990–2021: findings from the Global Burden of Disease Study 2021. Infectious Diseases of Poverty. 2024 Dec;13(1). Available from: https://doi.org/10.1186/s40249-024-01260-x

    1990 doi

  26. [34]

    Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

    Feigin VL. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019 May;18(5):459-80. Available from: https://doi.org/10.1016/s1474-4422(18)30499-x

    1990 doi

  27. [35]

    Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

    Ferrari AJ. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Psychiatry. 2022 Feb;9(2):137-50. Available from: https://doi.org/10.1016/s2215-0...

    1990 doi

  28. [36]

    Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019

    Momtazmanesh S. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019. eClinicalMedicine. 2023 May;59:101936. Available from: https://doi.org/10.1016/j.eclinm.2023.101936

    1990

  29. [37]

    Global Burden of Digestive Diseases: A Systematic Analysis of the Global Burden of Diseases Study, 1990 to 2019

    Wang Y . Global Burden of Digestive Diseases: A Systematic Analysis of the Global Burden of Diseases Study, 1990 to 2019. Gastroenterology. 2023 Sep;165(3):773-83.e15. Available from: https://doi.org/10.1053/j. gastro.2023.05.050

    1990 doi

  30. [38]

    Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021

    Ong KL. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2023 Jul;402(10397):203-34. Available from: https://doi.org/10.1016/s0140-6736(23)01301-6

    1990 doi

  31. [39]

    Global burden and trends of neglected tropical diseases from 1990 to 2019

    Lin Y . Global burden and trends of neglected tropical diseases from 1990 to 2019. Journal of Travel Medicine. 2022 May;29(3). Available from: https://doi.org/10.1093/jtm/taac031

    1990 doi

  32. [40]

    Global, regional, and national burden of HIV/AIDS, 1990–2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021

    Carter A. Global, regional, and national burden of HIV/AIDS, 1990–2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021. The Lancet HIV . 2024 Dec;11(12):e807-22. Available from: https://doi.org/10.1016/s2352-3018(24)00212-1

    1990 doi

  33. [41]

    Global burden and inequality of maternal and neonatal disorders: based on data from the 2019 Global Burden of Disease study

    Peng R. Global burden and inequality of maternal and neonatal disorders: based on data from the 2019 Global Burden of Disease study. QJM: An International Journal of Medicine. 2024 Feb;117(1):24-37. Available from: https://doi.org/10.1093/qjmed/hcad220

    2019 doi

  34. [42]

    Global burden and trends of transport injuries from 1990 to 2019: an observational trend study

    Wan R. Global burden and trends of transport injuries from 1990 to 2019: an observational trend study. Injury Prevention. 2023 Oct;29(5):418-24. Available from: https://doi.org/10.1136/ip-2023-044915

    1990 doi

  35. [43]

    Durkheim E. Suicide. Routledge. 2005 Aug. Available from: https://doi.org/10.4324/9780203994320

    2005 doi

  36. [44]

    Global burden of self-harm and interpersonal violence and influencing factors study 1990–2019: analysis of the global burden of disease study

    Zhou X. Global burden of self-harm and interpersonal violence and influencing factors study 1990–2019: analysis of the global burden of disease study. BMC Public Health. 2024 Apr;24(1). Available from: https: //doi.org/10.1186/s12889-024-18151-3 . 15

    1990 doi

Pith tools

Reviewed August 10, 2026 · model on record in the stance chip above.